PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Metrics, Inc. Introduces Melamine Contamination Test for Start Materials - FDA recommends that pharma companies test at-risk components, including gelatin capsule shells
Metrics, Inc. Introduces Melamine Contamination Test for Start Materials

 

NewswireToday - /newswire/ - Greenville , NC, United States, 2010/03/30 - FDA recommends that pharma companies test at-risk components, including gelatin capsule shells.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Metrics, Inc. has developed and validated a test that detects melamine in pharmaceutical start materials.

Metrics developed its test because of a recent U.S. Food and Drug Administration recommendation that urges pharmaceutical companies to test at-risk components for the presence of melamine.

Headquartered in Greenville, N.C., Metrics provides quality pharmaceutical formulation development; clinical material manufacturing for Phase I, II and III trials; commercial manufacturing; and analytical method development and validation services to the pharmaceutical industry.

The FDA recommendation follows two separate but widespread incidents of melamine contamination in consumable products. In both cases, the start materials were manufactured in China and exported to the United States, where they were used to make pet food and baby formula.

According to the FDA, melamine was added to start materials to bolster apparent protein content – thus making them appear more nutritious than they actually were.

Melamine alone is not necessarily dangerous. But in the presence of a similar compound called cyanuric acid, the two loosely associate and accumulate in the body, leading to kidney failure.

“There is no legitimate reason why melamine should be present in any pharmaceutical product,” said Dr. Jack E. Pender, senior scientist at Metrics Inc. “Because of the severity of melamine’s potential toxicity, it’s critical that companies accurately test at-risk start materials before they manufacture drug or food products.”

The motivation for melamine contamination can be found in how companies have tested start materials in the past.

To gauge the protein content of start materials, companies typically have tested for nitrogen, a fast and simple “barometer” for protein. But melamine is a nitrogen-based compound, so companies testing for nitrogen alone can’t distinguish melamine from the desired protein content.

Metrics has developed and validated a simple HPLC separation method with UV detection that is capable of detecting melamine down to the FDA recommended limit of 2.5 parts per million. For added reliability, Metrics evaluates matrix interferences on each sample tested and confirmed.

“Our method was designed to be simple in principle and easily adaptable to additional sample matrices as needed,” Pender said.

Pender reports that to date, pharmaceutical companies have most frequently requested melamine testing for gelatin capsule shells, which are derived from animal collagen.

“Because of the wide range of color combinations possible for gelatin capsule shells, the presence of various coloring agents means each gelatin capsule represents a different challenge for identifying and quantifying melamine at trace levels,” Pender said. “The test Metrics has developed easily adapts to those differences.”

The FDA recommends that companies test for melamine in start materials derived from milk or animal products, as well as start materials that contain more than 2.5 percent nitrogen in the compound by weight.

For a list of specific materials the FDA deems at risk for melamine contamination, please refer to the agency’s “Guidance for Industry: Pharmaceutical Components at Risk for Melamine Contamination,” which can be found on the FDA Website.

Since our start in 1994, Metrics Inc. has evolved from a start-up analytical laboratory into one of the fastest-growing contract pharmaceutical development and manufacturing organizations in the United States.

Metrics (metricsinc.com) offers the latest development and analytical equipment housed within a state-of-the-art, 92,000-square-foot cGMP facility. Facilities include a dedicated potent products suite; seven analytical laboratories; seven pharmaceutical development suites; seven large-scale manufacturing and packaging rooms for Phase III clinical trial and commercial manufacturing; stability storage; and a microbiology laboratory.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Metrics, Inc. Introduces Melamine Contamination Test for Start Materials

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Erin Smith - Sinclair-Co.com 
919-833-9102 esmith[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sinclair & Co. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)